Heart failure & cardiomyopathies
Utility of ECG-Vision for Surveillance of Left Ventricular Dysfunction in Patients With Hypertrophic Cardiomyopathy Initiated on Mavacamten
Authors' conclusion
In this single-center exploratory cohort of patients with obstructive hypertrophic cardiomyopathy receiving mavacamten, ECG-Vision left ventricular demonstrated high observed sensitivity and negative predictive value for TTE-defined LVSD, although estimates were imprecise because LVSD events were infrequent. These findings support prospective multicenter validation of AI-enabled ECG as a potential adjunctive triage tool.
Study context
- Population
- Patients with obstructive hypertrophic cardiomyopathy initiated on mavacamten at Morristown Medical Center/Atlantic Health between June 2022 and June 2025453 paired ECG-TTE observations
- Participants
- 147 patients
- Exposure
- Artificial intelligence (AI)-enabled ECG vs TTE-defined left ventricular systolic dysfunction (LVSD)
Main finding
As reported in the abstract
Mean age
65±14 years
Male
44%
Observational data: associations, not effects.
Further findings
| Outcome | AI-enabled ECG | TTE | |
|---|---|---|---|
| Diagnostic performance for LVSD at AI probability threshold of 20% | |||
| Sensitivity | 100% (95% CI, 68%-100%) | Not reported in the abstract | TTE: not reported in the abstract |
| Specificity | 75% (95% CI, 69%-82%) | Not reported in the abstract | TTE: not reported in the abstract |
| Positive predictive value | 7% (95% CI, 3%-11%) | Not reported in the abstract | TTE: not reported in the abstract |
| Negative predictive value | 100% (95% CI, 99%-100%) | Not reported in the abstract | TTE: not reported in the abstract |
- Diagnostic performance for LVSD at AI probability threshold of 20%: CIs accounting for repeated paired ECG-TTE observations within patients
LVSD event observations
- LVSD event observations among 453 paired ECG-TTE observations
- 8
Area under the curve
- Area under the curve
- 0.94 (95% CI, 0.90-0.98)
Patient-level classification, AI-enabled ECG vs echo-confirmed LVSD
- Concordant
- 127 of 147 patients (86%)
- Inconclusive
- 17 of 147 (12%)
- Discordant
- 3 of 147 (2%)
Original publication
Summarised from the published abstract; every number is checked against it